^
Association details:
| Biomarker: | GPC3 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + codrituzumab (RG7686) (GPC-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Published date:
10/09/2018
Excerpt:
Patients with advanced or metastatic HCC who had failed prior systemic therapy, GPC3 high expression...There was 1 confirmed PR, 10 SD (including 1 unconfirmed PR) among 18 evaluable patients and 6 of them had SD for more than 6 months before progression....Cod + Atezo combination was well-tolerated and showed antitumor activity in this advanced, previously treated and GPC3 highly expressed HCC patients.
DOI:
10.1093/annonc/mdy282.080
